Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism ULK1 inhibitors(Autophagy-related protein-1 homolog inhibitors), ULK2 inhibitors(unc-51 like autophagy activating kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC16H17F3N4O2 |
InChIKeyBQROJYIEHOOQBY-UHFFFAOYSA-N |
CAS Registry1884222-74-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Preclinical | US | 17 Nov 2020 |